Latest From Biotech Now

Answering the Call for Cures in Michigan

21st-Century-Cures--Free

This week, the Kalamazoo Gazette published an op-ed on how we can accelerate the discovery, development and delivery of treatments and cures for patients written by Stephen Rapundalo, President and CEO of MichBio, and BIO’s Jim Greenwood. The op-ed highlights the focus of roundtable discussions being held across the country as part of the 21st Century Cures Initiative. The U.S. House of Representatives’ Energy and Commerce Committee launched the initiative – led by Chairman Fred Read More >

Business and Investments, Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

USDA Illuminates the Economic Benefits of Moving Toward a Biobased Economy

USDA biopreferred

“A bioeconomy is one based on the use of research and innovation in the biological sciences to create economic activity and public benefit.” - White House (2012) The U.S. Department of Agriculture (USDA)  Secretary Tom Vilsack has recently announced the release of a comprehensive report synthesizing current literature that explores opportunities in the emerging bioeconomy.  The report, entitled Why Biobased?, was created by the USDA as a precursor for a more comprehensive economic study to be released in the coming months by the USDA BioPreferred Read More >

Environmental & Industrial  |  Leave a comment  |  Email This Post
Tags: , , , , ,

2014 BIO Investor Forum Fireside Chat with Nick Leschly and Chris Collins

bluebird bio

Nick Leschly has served as bluebird bio’s president and chief executive officer since September 2010. Previously, he served as interim chief executive officer from March 2010 to September 2010. Formerly a partner of Third Rock Ventures, L.P. since its founding in 2007, Mr. Leschly played an integral role in the overall formation, development and business strategy of several of Third Rock’s portfolio companies, including Agios Pharmaceuticals, Inc. and Edimer Pharmaceuticals, Inc. Prior to joining Third Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , ,

Blurred Lines: Investors Explain Their Re-Thinking of Traditional Private-Only or Public-Only Investment Strategies

DSC_8551

The recent expansion and acceleration of the biotech stock market has seen a new willingness and in some cases eagerness to pursue crossover investing in firms pre- and post-IPO. Venture capitalists have become less dogmatic about funding stage and equity share when positive returns seem nearly guaranteed and investment banks are engaging in discussions with entrepreneurs earlier than ever. Relatedly, corporate venture capital executives’ missions have broadened to consider more diverse forms of collaboration than Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , ,

Gene Therapies Discussed at 2014 BIO Investor Forum

BIO Investor Forum

Since the great excitements and disappointments of gene therapy’s first clinical era, the 1990s, researchers have revised traditional approaches and developed innovative new techniques, including CRISPR/cas-9, to edit genes with greater speed and precision than ever before.  Across a wide range of diseases, gene therapy is showing traction with fresh clinical results and attracting more than $600 million in venture capital in the past two years.  However, real challenges remain in delivery of therapies in Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , ,